This study was designed to randomize approximately 147 adult subjects.The patients were stratified according to whether the onset time was less than 14 days, and randomly divided into groups at a ratio of 1:1. The group received pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer.

This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤ 14 days and randomly divided into groups of 1: 1. This group only receives standard treatment

Novel Coronavirus Pneumonia

Pneumonia

Pirfenidone

Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer

pirfenidone

Tongji hospital affiliated to huazhong university of science and technology

A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection

A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection

Absolute change in pulse oxygen from baseline

Absolute change in blood gas from baseline

Absolute change in total score of King's brief questionnaire for interstitial Absolute change in total score of King's brief questionnaire for interstitial pulmonary disease (k-bild) from baseline at week 4

Time to death within 4 weeks due to respiratory problems

Time to disease progression or death within 4 weeks

Absolute change in viral nucleic acid from baseline

Pulmonary fibrosis survival symptoms absolute changes in dyspnea score from baseline

Absolute change in cough scores for pulmonary fibrosis survival symptoms from baseline

Huilan Zhang

Associate Professor of department of respiratory and critical care medicine, tongji hospital

This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤14 days and randomly divided into groups of 1: 1, receiving standard treatment or pirfenidone orally 3 times a day, 2 tablets each time. The course is 4 weeks or more. Subjects and all research center staff were not blinded.

All participants to receive study intervention.

Retinitis Pigmentosa

After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).

NAC effervescent tablets

Wilmer Eye Institute at Johns Hopkins University

FIGHT-RP 1 Extension Study

A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa

Blood pressure in mmHg will be used in assessing tolerability of N-Acetylcysteine.

Participants will be assessed for the occurrence of any drug-related symptoms which includes nausea, stomach upset, diarrhea, heartburn, constipation, and vomiting. Based on the number and severity of the symptoms, the physician would conclude whether the patient is tolerating the medication or not.

Medication diary provided to participants will be reviewed to see if participants are taking the medication within the designated time frame.

Medication diary provided to participants will be reviewed to see if participants are taking the medication twice a day

Scoring is determined by the number of letters gained or lost per month using Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score and visual acuity score together with an overall score range of 0 to 20/20 where 0 is the worst vision and 20/20 is the best.

Microperimetry (MAIA) is used to test whether there is an increase or decrease in sensitivity (dB) in the retina after initiation of N-Acetylcysteine

This will be assessed by spectral domain optical coherence tomography (SD-OCT) after initiation of N-Acetylcysteine.

This will be calculated from the proportions of reduced glutathione and oxidized glutathione in the aqueous.

Johns Hopkins University

Tablet Tadalafil 20 mg every alternate day

Lung Diseases, Interstitial

Tab. Tadalafil 20 mg every other day for 6 months

Tadalafil

Shape , size, color and odor matched Tab. of inert material every other day for 6 months

Placebo

SGPGIMS

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

To assess the change in FVC (expressed as a percentage of the predicted value) from baseline values at the end of 6 months

To assess the improvement in dyspnoea (as measured by Mehler dyspnoea index) at the end of 6 month

To assess improvement in 6 min walk test at the end of 6 months

To assess the change in DLCO from baseline values at the end of 6 months

To assess the change in total lung capacity from baseline values at the end of 6 months

To assess the change in the disability index of the Health Assessment Questionnaire (S HAQ) at 6 months from baseline

To assess the change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) from baseline to end of 6 months

Vikas Agarwal

Additional Professor

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Treatment with low dose oral interferon alpha lozenges taken 3 times daily (approximately 6 hours apart). Lozenge is to be dissolved under tongue or by moving around in mouth.

Interferon Alpha

Sex: Female, Male

Region of Enrollment

Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT & pulmonary function. The same radiologist did the comparsion for all subjects.

Minimal/no Progression (1 yr) by High Resolution Computed Tomography (HRCT) & Pulmonary Function

Minimal/no Change in Quality of Life

changes in cough status after treatment for 1 month.

Participants With Change in Cough

Overall Study

Lorenz Lutherer, MD, PhD

Respiratory Tract Diseases

Lung Diseases